Recent Updates
Recently added Catalysts
SINT

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT

Key Takeaway: Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer Healthcare Executive to Lead Strategic Growth Initiatives Lake City, UT - November 19, 2024 (Globe NEWSWIRE) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), an advanced ceramics company th

Full Press Release Details

Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer
Healthcare Executive to Lead Strategic Growth Initiatives
Lake City, UT - November 19, 2024 (Globe NEWSWIRE) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or
the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for
medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In
this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations.
Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare sector. His
career began on Wall Street as a stockbroker, transitioning into investment banking roles at various firms in New York City. He co-founded
Creation Capital LLC and Creation Capital Advisors, investment banking firms with offices in New York and Austin, Texas, focusing on
founding and funding breakthrough healthcare technologies.
his career, Mr. Honigblum has raised over half a billion dollars for various ventures. Notably, Mr. Honigblum was instrumental in providing
early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2
breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics
company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for $620 million.
appointment as Chief Strategy Officer reflects our confidence in his ability to elevate SINTX's financial and strategic position,"
said Eric K. Olson, CEO of SINTX Technologies. "His successful career in emerging technologies and deep investment banking knowledge
will be invaluable as we pursue new development opportunities, strengthen investor relationships, and drive our corporate strategy and
Honigblum's deep understanding of the Company's mission and strategic goals, coupled with his experience as a former member
of the board of Amedica, the predecessor of SINTX, positions him to drive the Company's corporate strategy effectively.
am honored to join SINTX at this pivotal juncture," said Gregg R. Honigblum, Chief Strategy Officer. "The Company's
ongoing development of pioneering technologies in the medical device sector positions it at the forefront of commercialization. I look
forward to contributing to the team's efforts in enhancing shareholder value and drive the Company's vision forward."
more information, please visit www.sintx.com
SINTX Technologies, Inc.
Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and
technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products
have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter
new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or
its materials platform, visit www.sintx.com.
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA")
that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate,"
"believe," "project," "estimate," "expect," "strategy," "future,"
"likely," "may," "should," "will" and similar references to future periods. Examples
of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new
avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.
are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and
reflect management's current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which
are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking
statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in
the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product
opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially
from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on
Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly
revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as
and Media Inquiries for SINTX:
Last updated: Nov 19, 2024